CD8 Epitope Escape and Reversion in Acute HCV Infection
In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70–80% of individuals develop persistent infection. Although viral escape from CD8 responses has been il...
Saved in:
| Published in | The Journal of experimental medicine Vol. 200; no. 12; pp. 1593 - 1604 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
The Rockefeller University Press
20.12.2004
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0022-1007 1540-9538 1892-1007 |
| DOI | 10.1084/jem.20041006 |
Cover
Loading…
| Abstract | In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70–80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8–restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon γ enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8–associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution. |
|---|---|
| AbstractList | In the setting of acute hepatitis C virus (HCV) infection, robust HCV- specific CD8 super(+) cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70-80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8-restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon gamma enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV- infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele- specific selection pressures at the population level. Interestingly, transmission of an HLA-B8-associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8 super(+) T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution. In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70–80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8–restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon γ enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8–associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution. In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70-80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8-restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon gamma enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8-associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution.In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70-80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8-restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon gamma enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8-associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution. In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8 + cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70–80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8–restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon γ enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8–associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8 + T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution. In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70-80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8-restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon gamma enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8-associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution. |
| Author | Reyor, Laura L. Chung, Raymond T. Pillay, Thillagavathie Gandhi, Rajesh T. Bhardwaj, Nina Ouchi, Kei Timm, Joerg Lauer, Georg M. Walker, Bruce D. Klenerman, Paul Kavanagh, Daniel G. Allen, Todd M. Sheridan, Isabelle zur Wiesch, Julian Schulze Kim, Arthur Y. Lucas, Michaela |
| AuthorAffiliation | 2 Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 3 Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, Oxford OX1 3SY, England, UK 4 New York University School of Medicine, New York, NY 10016 1 Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute |
| AuthorAffiliation_xml | – name: 1 Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute – name: 4 New York University School of Medicine, New York, NY 10016 – name: 2 Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 – name: 3 Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, Oxford OX1 3SY, England, UK |
| Author_xml | – sequence: 1 givenname: Joerg surname: Timm fullname: Timm, Joerg – sequence: 2 givenname: Georg M. surname: Lauer fullname: Lauer, Georg M. – sequence: 3 givenname: Daniel G. surname: Kavanagh fullname: Kavanagh, Daniel G. – sequence: 4 givenname: Isabelle surname: Sheridan fullname: Sheridan, Isabelle – sequence: 5 givenname: Arthur Y. surname: Kim fullname: Kim, Arthur Y. – sequence: 6 givenname: Michaela surname: Lucas fullname: Lucas, Michaela – sequence: 7 givenname: Thillagavathie surname: Pillay fullname: Pillay, Thillagavathie – sequence: 8 givenname: Kei surname: Ouchi fullname: Ouchi, Kei – sequence: 9 givenname: Laura L. surname: Reyor fullname: Reyor, Laura L. – sequence: 10 givenname: Julian Schulze surname: zur Wiesch fullname: zur Wiesch, Julian Schulze – sequence: 11 givenname: Rajesh T. surname: Gandhi fullname: Gandhi, Rajesh T. – sequence: 12 givenname: Raymond T. surname: Chung fullname: Chung, Raymond T. – sequence: 13 givenname: Nina surname: Bhardwaj fullname: Bhardwaj, Nina – sequence: 14 givenname: Paul surname: Klenerman fullname: Klenerman, Paul – sequence: 15 givenname: Bruce D. surname: Walker fullname: Walker, Bruce D. – sequence: 16 givenname: Todd M. surname: Allen fullname: Allen, Todd M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15611288$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkd1LwzAUxYNM3Ie--Sx98snOm7Rp2hdh1OmEgSDqa8jSW83o0tl0A_97M7b5heDThZtfTk7O6ZOOrS0SckphSCGNL-e4GDKAmAIkB6RHeQxhxqO0Q3oAjIV-L7qk79wcgMYxT45Il_KEUpamPSLy6zQYL01bLzEYO638ULYIHnCNjTO1DYwNRnrVYjDJn4M7W6Ju_fqYHJaqcniymwPydDN-zCfh9P72Lh9NQx2LrA21orMoYaBAlFmBHJXgWquEFSlTHEvvUBcpcK5iwWiUzRQXimblTHAEKDAakKut7nI1W2Ch0baNquSyMQvVvMtaGfnzxJpX-VKvJWPUp8K9wPlOoKnfVuhauTBOY1Upi_XKyUTQNAH_9n8gFSKOINmAZ98tfXrZh-qBiy2gm9q5BssvBOSmM-k7k_vOPM5-4dq0ahOy_5Cp_r70ARefmJY |
| CitedBy_id | crossref_primary_10_1007_s12026_009_8152_3 crossref_primary_10_1089_vim_2015_0093 crossref_primary_10_1371_journal_ppat_1009596 crossref_primary_10_3389_fimmu_2022_832206 crossref_primary_10_1016_j_antiviral_2008_10_003 crossref_primary_10_1016_j_virusres_2006_08_012 crossref_primary_10_1007_s00251_006_0185_3 crossref_primary_10_1084_jem_20100388 crossref_primary_10_1016_j_meegid_2013_07_030 crossref_primary_10_1111_jvh_13011 crossref_primary_10_1007_s00262_005_0007_8 crossref_primary_10_4254_wjh_v7_i1_53 crossref_primary_10_1017_S1462399408000847 crossref_primary_10_1084_jem_20042284 crossref_primary_10_3390_pathogens13040331 crossref_primary_10_1038_s41467_019_09105_0 crossref_primary_10_1016_j_antiviral_2012_07_006 crossref_primary_10_1053_j_gastro_2006_12_008 crossref_primary_10_1098_rspb_2006_3563 crossref_primary_10_1073_pnas_1312772110 crossref_primary_10_1371_journal_ppat_1006991 crossref_primary_10_1371_journal_pone_0000791 crossref_primary_10_1128_JVI_02265_09 crossref_primary_10_1038_s41590_021_00982_6 crossref_primary_10_1002_hep_25575 crossref_primary_10_1089_vim_2008_0046 crossref_primary_10_1016_j_coviro_2021_07_003 crossref_primary_10_1038_s41598_017_15605_0 crossref_primary_10_1099_vir_0_82826_0 crossref_primary_10_1097_COH_0b013e32834b879e crossref_primary_10_1111_imm_12703 crossref_primary_10_1038_sj_gene_6364368 crossref_primary_10_1053_j_gastro_2009_06_040 crossref_primary_10_1128_JVI_01369_07 crossref_primary_10_1128_JVI_00995_07 crossref_primary_10_1172_JCI39133 crossref_primary_10_4049_jimmunol_181_9_6435 crossref_primary_10_1016_j_jhep_2008_11_010 crossref_primary_10_1016_j_virusres_2007_02_001 crossref_primary_10_1038_s41579_018_0120_2 crossref_primary_10_1111_jvh_13051 crossref_primary_10_1073_pnas_1713957115 crossref_primary_10_1186_1743_422X_8_377 crossref_primary_10_1016_j_clim_2008_03_525 crossref_primary_10_1002_hep_28294 crossref_primary_10_1038_ni1241 crossref_primary_10_1007_s11262_007_0179_8 crossref_primary_10_1038_emi_2013_14 crossref_primary_10_1016_j_virol_2006_05_015 crossref_primary_10_1007_s11908_007_0003_6 crossref_primary_10_2217_17460794_1_6_703 crossref_primary_10_1016_j_vaccine_2009_02_088 crossref_primary_10_1111_j_1558_5646_2009_00727_x crossref_primary_10_1128_JVI_01354_06 crossref_primary_10_2217_bmm_11_19 crossref_primary_10_1128_JVI_00487_07 crossref_primary_10_1007_s00005_015_0364_8 crossref_primary_10_1016_j_meegid_2019_02_025 crossref_primary_10_3390_vaccines4030027 crossref_primary_10_1128_JVI_79_15_9369_9380_2005 crossref_primary_10_1586_14760584_8_3_333 crossref_primary_10_1007_s11908_007_0051_y crossref_primary_10_1002_hep_21541 crossref_primary_10_1086_500944 crossref_primary_10_1093_infdis_jis762 crossref_primary_10_1016_j_immuni_2013_12_010 crossref_primary_10_1371_journal_ppat_1000186 crossref_primary_10_1016_j_cels_2023_11_001 crossref_primary_10_1371_journal_ppat_1002243 crossref_primary_10_1111_j_1872_034X_2007_00220_x crossref_primary_10_2169_internalmedicine_45_1530 crossref_primary_10_1371_journal_pone_0171217 crossref_primary_10_1128_JVI_01993_15 crossref_primary_10_4049_jimmunol_1103008 crossref_primary_10_1371_journal_pone_0000649 crossref_primary_10_1128_JVI_02276_06 crossref_primary_10_1021_bm400626w crossref_primary_10_1002_eji_201141593 crossref_primary_10_1016_j_vaccine_2006_03_009 crossref_primary_10_14218_JCTH_2020_00095 crossref_primary_10_1016_j_immuni_2017_09_006 crossref_primary_10_1371_journal_pone_0142349 crossref_primary_10_1128_JVI_00779_11 crossref_primary_10_1371_journal_pone_0016797 crossref_primary_10_1053_j_gastro_2007_01_010 crossref_primary_10_1016_j_antiviral_2014_11_009 crossref_primary_10_1128_JVI_01179_08 crossref_primary_10_1016_j_mehy_2012_08_026 crossref_primary_10_2217_fvl_10_84 crossref_primary_10_1128_JVI_02837_15 crossref_primary_10_1038_mt_2013_119 crossref_primary_10_1177_026119291003800602 crossref_primary_10_4254_wjh_v13_i10_1234 crossref_primary_10_1128_JVI_02271_09 crossref_primary_10_1007_s00430_014_0372_z crossref_primary_10_1111_j_1365_3083_2006_01850_x crossref_primary_10_1189_jlb_4RI0214_126R crossref_primary_10_3389_fimmu_2022_1045498 crossref_primary_10_1002_hep_22773 crossref_primary_10_3390_v14020215 crossref_primary_10_1099_vir_0_027987_0 crossref_primary_10_1016_j_virusres_2009_11_001 crossref_primary_10_1016_j_coviro_2021_08_002 crossref_primary_10_2217_fmb_09_8 crossref_primary_10_1053_j_gastro_2019_02_003 crossref_primary_10_4049_jimmunol_1401357 crossref_primary_10_1128_JVI_01700_07 crossref_primary_10_1002_hep_22422 crossref_primary_10_1007_s11377_006_0015_z crossref_primary_10_1111_j_1365_2893_2006_00792_x crossref_primary_10_1111_mpp_12908 crossref_primary_10_1155_2013_673240 crossref_primary_10_4049_jimmunol_1003167 crossref_primary_10_1186_1743_422X_10_295 crossref_primary_10_1016_j_jcis_2019_03_022 crossref_primary_10_1016_j_coviro_2018_08_015 crossref_primary_10_1038_nm_3351 crossref_primary_10_1002_hep_23096 crossref_primary_10_3390_v14020198 crossref_primary_10_4049_jimmunol_1200219 crossref_primary_10_3390_ijms21165644 crossref_primary_10_1016_j_jhep_2016_07_037 crossref_primary_10_3390_v1020276 crossref_primary_10_1016_j_vaccine_2024_05_080 crossref_primary_10_1371_journal_ppat_1000143 crossref_primary_10_1016_j_virol_2009_01_020 crossref_primary_10_1111_j_1365_2893_2010_01294_x crossref_primary_10_1016_j_diagmicrobio_2023_116104 crossref_primary_10_1053_j_gastro_2008_11_049 crossref_primary_10_3390_v11020106 crossref_primary_10_1038_icb_2009_24 crossref_primary_10_1371_journal_pone_0130420 crossref_primary_10_1089_vim_2007_0064 crossref_primary_10_1002_hep_24076 crossref_primary_10_1053_j_gastro_2006_11_044 crossref_primary_10_1371_journal_pcbi_1000565 crossref_primary_10_1093_bib_bbad264 crossref_primary_10_1038_nri1573 crossref_primary_10_1128_JVI_01580_07 crossref_primary_10_1371_journal_ppat_1006235 crossref_primary_10_1128_JVI_00912_06 crossref_primary_10_1053_j_gastro_2018_08_060 crossref_primary_10_3748_wjg_v21_i42_11984 crossref_primary_10_2217_17460794_2_4_319 crossref_primary_10_1128_JVI_01590_14 crossref_primary_10_3390_v10110645 crossref_primary_10_1086_504327 crossref_primary_10_1016_j_jhep_2019_01_034 crossref_primary_10_2217_pgs_09_121 crossref_primary_10_3390_cells8040305 crossref_primary_10_1128_JVI_02445_12 crossref_primary_10_1089_vim_2017_0001 crossref_primary_10_1128_JVI_05603_11 crossref_primary_10_1007_s00005_012_0184_z crossref_primary_10_1007_s00705_022_05375_0 crossref_primary_10_1016_j_coviro_2016_01_002 crossref_primary_10_1016_j_virol_2007_04_003 crossref_primary_10_1016_j_coviro_2017_03_013 crossref_primary_10_1016_j_jhep_2020_09_022 crossref_primary_10_1371_journal_ppat_1002529 crossref_primary_10_1016_j_jhep_2007_12_014 crossref_primary_10_1002_lt_20423 crossref_primary_10_1556_OH_2011_29113 crossref_primary_10_1517_14712590902988444 crossref_primary_10_1111_j_1365_2893_2005_00676_x crossref_primary_10_1128_JVI_01543_07 crossref_primary_10_1002_hep_20856 crossref_primary_10_1007_s11901_006_0007_y crossref_primary_10_1002_hep_21702 crossref_primary_10_1042_CS20060171 crossref_primary_10_1002_hep_22242 crossref_primary_10_1089_vim_2006_19_458 crossref_primary_10_1002_eji_200526067 crossref_primary_10_1098_rsos_150661 crossref_primary_10_1099_vir_0_2008_000992_0 crossref_primary_10_1101_cshperspect_a036954 crossref_primary_10_1371_journal_ppat_1009391 crossref_primary_10_1515_BC_2008_061 crossref_primary_10_1128_JVI_01231_06 crossref_primary_10_1128_JVI_00997_08 crossref_primary_10_1002_hep_30894 crossref_primary_10_1016_j_jhep_2014_06_035 crossref_primary_10_1146_annurev_immunol_25_022106_141602 crossref_primary_10_1002_med_20157 crossref_primary_10_1016_j_jhep_2010_06_011 crossref_primary_10_1038_nature04079 crossref_primary_10_1053_j_gastro_2011_02_060 crossref_primary_10_1128_JVI_01440_12 crossref_primary_10_21518_ms2023_139 crossref_primary_10_1002_hep_23101 crossref_primary_10_1016_j_meegid_2017_12_015 crossref_primary_10_1002_hep_21162 crossref_primary_10_1101_cshperspect_a036947 crossref_primary_10_1111_j_1574_6976_2011_00319_x crossref_primary_10_4049_jimmunol_181_9_6361 crossref_primary_10_1016_j_jhep_2008_11_023 crossref_primary_10_4049_jimmunol_175_11_7519 crossref_primary_10_1128_JVI_79_20_12979_12988_2005 crossref_primary_10_1586_14787210_6_4_463 crossref_primary_10_1097_QAD_0b013e328330ed24 crossref_primary_10_1155_2010_548280 crossref_primary_10_3389_fimmu_2014_00274 crossref_primary_10_1016_j_jhep_2004_12_013 crossref_primary_10_1157_13111005 crossref_primary_10_1002_hep_21049 crossref_primary_10_3390_v11080683 crossref_primary_10_1002_hep_22379 crossref_primary_10_1128_JVI_02654_10 crossref_primary_10_1084_jem_20050808 crossref_primary_10_1016_j_virusres_2016_11_023 crossref_primary_10_1172_JCI36587 crossref_primary_10_3390_pathogens10121619 crossref_primary_10_4049_jimmunol_0803658 crossref_primary_10_1084_jem_20050122 crossref_primary_10_1084_jem_20050121 crossref_primary_10_1016_j_jhep_2014_09_009 crossref_primary_10_1182_blood_2007_01_069583 crossref_primary_10_1016_j_ecofro_2024_10_005 crossref_primary_10_1186_1471_2148_11_131 crossref_primary_10_1016_j_antiviral_2009_02_203 crossref_primary_10_1016_j_molimm_2006_06_003 crossref_primary_10_1128_JVI_03812_13 crossref_primary_10_1258_ebm_2011_011062 crossref_primary_10_4049_jimmunol_181_12_8215 |
| Cites_doi | 10.1084/jem.194.10.1395 10.1128/JVI.76.12.6104-6113.2002 10.1038/nm0297-205 10.1128/JVI.78.13.7069-7078.2004 10.1126/science.288.5464.339 10.1053/j.gastro.2004.06.005 10.1126/science.1088774 10.1016/S0165-2478(02)00224-9 10.1172/JCI118287 10.1038/82161 10.1128/JVI.76.6.2817-2826.2002 10.1172/JCI119778 10.1016/S1074-7613(00)80044-8 10.1056/NEJM200107053450107 10.1016/S1471-4906(03)00178-9 10.1111/j.1399-0039.1995.tb03127.x 10.1016/S0016-5085(99)70353-7 10.1128/JVI.78.2.630-641.2004 10.1126/science.274.5284.94 10.1172/JCI200318509 10.1053/jhep.2002.35344 10.1084/jem.20031982 10.1172/JCI118931 10.1128/JVI.78.3.1324-1332.2004 10.1128/JVI.76.24.12423-12434.2002 10.1128/jvi.71.2.1089-1096.1997 10.1038/35030124 10.1016/S0140-6736(95)91691-1 10.1073/pnas.88.24.11047 10.1038/nm992 10.4049/jimmunol.169.6.3447 10.1084/jem.191.9.1499 10.1038/354453a0 10.1128/JVI.78.7.3447-3454.2004 10.1046/j.1365-2249.2002.01840.x 10.1172/JCI200420985 10.1053/gast.2001.21212 10.1084/jem.20030239 10.1038/nbt0498-364 10.1016/S1074-7613(01)00245-X 10.1128/JVI.75.12.5550-5558.2001 10.1007/BF00945026 10.1084/jem.191.11.1853 10.1086/381097 10.1038/nm998 10.1128/jvi.67.7.4365-4368.1993 10.1016/S0198-8859(01)00298-1 10.1002/1521-4141(200108)31:8<2388::AID-IMMU2388>3.0.CO;2-L 10.1073/pnas.96.10.5692 10.1002/hep.510300403 10.1093/genetics/155.1.431 |
| ContentType | Journal Article |
| Copyright | Copyright © 2004, The Rockefeller University Press |
| Copyright_xml | – notice: Copyright © 2004, The Rockefeller University Press |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM |
| DOI | 10.1084/jem.20041006 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1540-9538 1892-1007 |
| EndPage | 1604 |
| ExternalDocumentID | PMC2212005 15611288 10_1084_jem_20041006 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI031563 – fundername: NIAID NIH HHS grantid: AI31563 – fundername: Wellcome Trust |
| GroupedDBID | --- -~X .55 .GJ 0VX 18M 29K 2WC 36B 3O- 4.4 53G 5GY 5RE 5VS 9M8 AAYXX ABOCM ABZEH ACGFO ACNCT ACPRK ADBBV AENEX AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C45 CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB F5P F9R GX1 H13 HYE H~9 IH2 K-O KQ8 L7B MVM N4W N9A O5R O5S OHT OK1 P2P P6G R.V RHI SJN TR2 TRP UHB VH1 W8F WOQ X7M ZGI CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 5PM |
| ID | FETCH-LOGICAL-c479t-ca1b3620a07f9de5ea75cca62d82a5ef002cd8055a472139ba57a19fb75e00de3 |
| ISSN | 0022-1007 |
| IngestDate | Thu Aug 21 17:42:15 EDT 2025 Fri Jul 11 01:01:13 EDT 2025 Fri Jul 11 06:41:48 EDT 2025 Thu Apr 03 06:57:24 EDT 2025 Tue Jul 01 03:30:20 EDT 2025 Thu Apr 24 23:11:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c479t-ca1b3620a07f9de5ea75cca62d82a5ef002cd8055a472139ba57a19fb75e00de3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Address correspondence to Todd M. Allen, Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Bldg. 149, 13th St., Rm. 6618 B, Boston, MA 02114. Phone: (617) 726-7846; Fax: (617) 724-8586; email: tallen2@partners.org Abbreviations used in this paper: HCV, hepatitis C virus; ICS, intracellular cytokine staining; ML, maximum likelihood. J. Timm and G.M. Lauer contributed equally to this work. |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC2212005 |
| PMID | 15611288 |
| PQID | 17743061 |
| PQPubID | 23462 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2212005 proquest_miscellaneous_67186021 proquest_miscellaneous_17743061 pubmed_primary_15611288 crossref_primary_10_1084_jem_20041006 crossref_citationtrail_10_1084_jem_20041006 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2004-12-20 2004-Dec-20 20041220 |
| PublicationDateYYYYMMDD | 2004-12-20 |
| PublicationDate_xml | – month: 12 year: 2004 text: 2004-12-20 day: 20 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of experimental medicine |
| PublicationTitleAlternate | J Exp Med |
| PublicationYear | 2004 |
| Publisher | The Rockefeller University Press |
| Publisher_xml | – name: The Rockefeller University Press |
| References | (2023072512363768700_BIB1) 2001; 345 (2023072512363768700_BIB7) 2003; 197 (2023072512363768700_BIB6) 2001; 194 (2023072512363768700_BIB20) 2003; 85 (2023072512363768700_BIB9) 1996; 98 (2023072512363768700_BIB26) 2004; 78 (2023072512363768700_BIB38) 1995; 96 (2023072512363768700_BIB8) 2003; 302 (2023072512363768700_BIB24) 1991; 88 (2023072512363768700_BIB34) 1996; 274 (2023072512363768700_BIB32) 2002; 128 (2023072512363768700_BIB35) 1995; 46 2023072512363768700_BIB36 (2023072512363768700_BIB46) 1997; 3 (2023072512363768700_BIB31) 1999; 30 (2023072512363768700_BIB48) 1997; 71 (2023072512363768700_BIB42) 2004; 114 (2023072512363768700_BIB3) 1999; 117 (2023072512363768700_BIB44) 2004; 10 (2023072512363768700_BIB11) 2002; 36 (2023072512363768700_BIB12) 2003; 112 (2023072512363768700_BIB19) 2001; 120 (2023072512363768700_BIB2) 1995; 346 (2023072512363768700_BIB51) 2004; 127 (2023072512363768700_BIB49) 2004; 38 (2023072512363768700_BIB13) 1999; 96 (2023072512363768700_BIB28) 1997; 100 (2023072512363768700_BIB33) 2002; 76 (2023072512363768700_BIB21) 2000; 6 (2023072512363768700_BIB52) 2001; 75 (2023072512363768700_BIB23) 2000; 407 (2023072512363768700_BIB30) 2000; 288 (2023072512363768700_BIB14) 2001; 31 (2023072512363768700_BIB10) 2002; 76 (2023072512363768700_BIB37) 2000; 155 (2023072512363768700_BIB43) 1998; 16 (2023072512363768700_BIB50) 1993; 67 (2023072512363768700_BIB16) 2003; 24 (2023072512363768700_BIB39) 2004; 78 (2023072512363768700_BIB17) 2002; 76 (2023072512363768700_BIB27) 2001; 15 (2023072512363768700_BIB47) 2001; 62 (2023072512363768700_BIB45) 2004; 10 (2023072512363768700_BIB41) 2004; 78 (2023072512363768700_BIB29) 2004; 78 (2023072512363768700_BIB5) 1999; 10 (2023072512363768700_BIB4) 2000; 191 (2023072512363768700_BIB40) 2004; 199 (2023072512363768700_BIB15) 1997; 19 (2023072512363768700_BIB22) 1991; 354 (2023072512363768700_BIB25) 2000; 191 (2023072512363768700_BIB18) 2002; 169 15067030 - J Exp Med. 2004 Apr 5;199(7):905-15 12438568 - J Virol. 2002 Dec;76(24):12423-34 8810254 - Science. 1996 Oct 4;274(5284):94-6 11985510 - Clin Exp Immunol. 2002 May;128(2):195-203 9266632 - Springer Semin Immunopathol. 1997;19(1):69-83 14966520 - Nat Med. 2004 Mar;10(3):275-81 14770175 - Nat Med. 2004 Mar;10(3):282-9 10764648 - Science. 2000 Apr 14;288(5464):339-44 12527224 - Immunol Lett. 2003 Jan 22;85(2):165-71 12810686 - J Exp Med. 2003 Jun 16;197(12):1645-55 14576438 - Science. 2003 Oct 24;302(5645):659-62 15254592 - J Clin Invest. 2004 Jul;114(2):250-9 11754811 - Immunity. 2001 Dec;15(6):883-95 12218168 - J Immunol. 2002 Sep 15;169(6):3447-58 9018240 - Nat Med. 1997 Feb;3(2):205-11 10229187 - Immunity. 1999 Apr;10(4):439-49 11861849 - J Virol. 2002 Mar;76(6):2817-26 11439948 - N Engl J Med. 2001 Jul 5;345(1):41-52 11500822 - Eur J Immunol. 2001 Aug;31(8):2388-94 8823309 - J Clin Invest. 1996 Sep 15;98(6):1432-40 9410918 - J Clin Invest. 1997 Nov 1;100(9):2376-85 11714747 - J Exp Med. 2001 Nov 19;194(10):1395-406 12198669 - Hepatology. 2002 Sep;36(3):743-54 15194783 - J Virol. 2004 Jul;78(13):7069-78 10498657 - Hepatology. 1999 Oct;30(4):1037-44 14694094 - J Virol. 2004 Jan;78(2):630-41 14722287 - J Virol. 2004 Feb;78(3):1324-32 12909460 - Trends Immunol. 2003 Aug;24(8):456-64 15016867 - J Virol. 2004 Apr;78(7):3447-54 7593618 - J Clin Invest. 1995 Nov;96(5):2311-21 10318946 - Proc Natl Acad Sci U S A. 1999 May 11;96(10):5692-7 15362033 - Gastroenterology. 2004 Sep;127(3):764-76 10790415 - Genetics. 2000 May;155(1):431-49 10500077 - Gastroenterology. 1999 Oct;117(4):933-41 12021343 - J Virol. 2002 Jun;76(12):6104-13 12975468 - J Clin Invest. 2003 Sep;112(6):831-42 8389933 - J Virol. 1993 Jul;67(7):4365-8 11100119 - Nat Med. 2000 Dec;6(12):1348-54 7475549 - Lancet. 1995 Oct 14;346(8981):1006-7 8995629 - J Virol. 1997 Feb;71(2):1089-96 11543903 - Hum Immunol. 2001 Sep;62(9):1009-30 1722316 - Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11047-51 10839802 - J Exp Med. 2000 Jun 5;191(11):1853-67 14727218 - Clin Infect Dis. 2004 Feb 1;38(3):433-7 11014195 - Nature. 2000 Sep 21;407(6802):386-90 10790425 - J Exp Med. 2000 May 1;191(9):1499-512 8838344 - Tissue Antigens. 1995 Nov;46(5):355-67 9555728 - Nat Biotechnol. 1998 Apr;16(4):364-9 11356962 - J Virol. 2001 Jun;75(12):5550-8 1721107 - Nature. 1991 Dec 12;354(6353):453-9 11159892 - Gastroenterology. 2001 Feb;120(2):512-24 |
| References_xml | – volume: 194 start-page: 1395 year: 2001 ident: 2023072512363768700_BIB6 publication-title: J. Exp. Med. doi: 10.1084/jem.194.10.1395 – ident: 2023072512363768700_BIB36 – volume: 76 start-page: 6104 year: 2002 ident: 2023072512363768700_BIB10 publication-title: J. Virol. doi: 10.1128/JVI.76.12.6104-6113.2002 – volume: 3 start-page: 205 year: 1997 ident: 2023072512363768700_BIB46 publication-title: Nat. Med. doi: 10.1038/nm0297-205 – volume: 78 start-page: 7069 year: 2004 ident: 2023072512363768700_BIB39 publication-title: J. Virol. doi: 10.1128/JVI.78.13.7069-7078.2004 – volume: 288 start-page: 339 year: 2000 ident: 2023072512363768700_BIB30 publication-title: Science. doi: 10.1126/science.288.5464.339 – volume: 127 start-page: 764 year: 2004 ident: 2023072512363768700_BIB51 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2004.06.005 – volume: 302 start-page: 659 year: 2003 ident: 2023072512363768700_BIB8 publication-title: Science. doi: 10.1126/science.1088774 – volume: 85 start-page: 165 year: 2003 ident: 2023072512363768700_BIB20 publication-title: Immunol. Lett. doi: 10.1016/S0165-2478(02)00224-9 – volume: 96 start-page: 2311 year: 1995 ident: 2023072512363768700_BIB38 publication-title: J. Clin. Invest. doi: 10.1172/JCI118287 – volume: 6 start-page: 1348 year: 2000 ident: 2023072512363768700_BIB21 publication-title: Nat. Med. doi: 10.1038/82161 – volume: 76 start-page: 2817 year: 2002 ident: 2023072512363768700_BIB33 publication-title: J. Virol. doi: 10.1128/JVI.76.6.2817-2826.2002 – volume: 100 start-page: 2376 year: 1997 ident: 2023072512363768700_BIB28 publication-title: J. Clin. Invest. doi: 10.1172/JCI119778 – volume: 10 start-page: 439 year: 1999 ident: 2023072512363768700_BIB5 publication-title: Immunity. doi: 10.1016/S1074-7613(00)80044-8 – volume: 345 start-page: 41 year: 2001 ident: 2023072512363768700_BIB1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200107053450107 – volume: 24 start-page: 456 year: 2003 ident: 2023072512363768700_BIB16 publication-title: Trends Immunol. doi: 10.1016/S1471-4906(03)00178-9 – volume: 46 start-page: 355 year: 1995 ident: 2023072512363768700_BIB35 publication-title: Tissue Antigens. doi: 10.1111/j.1399-0039.1995.tb03127.x – volume: 117 start-page: 933 year: 1999 ident: 2023072512363768700_BIB3 publication-title: Gastroenterology. doi: 10.1016/S0016-5085(99)70353-7 – volume: 78 start-page: 630 year: 2004 ident: 2023072512363768700_BIB26 publication-title: J. Virol. doi: 10.1128/JVI.78.2.630-641.2004 – volume: 274 start-page: 94 year: 1996 ident: 2023072512363768700_BIB34 publication-title: Science. doi: 10.1126/science.274.5284.94 – volume: 112 start-page: 831 year: 2003 ident: 2023072512363768700_BIB12 publication-title: J. Clin. Invest. doi: 10.1172/JCI200318509 – volume: 36 start-page: 743 year: 2002 ident: 2023072512363768700_BIB11 publication-title: Hepatology. doi: 10.1053/jhep.2002.35344 – volume: 199 start-page: 905 year: 2004 ident: 2023072512363768700_BIB40 publication-title: J. Exp. Med. doi: 10.1084/jem.20031982 – volume: 98 start-page: 1432 year: 1996 ident: 2023072512363768700_BIB9 publication-title: J. Clin. Invest. doi: 10.1172/JCI118931 – volume: 78 start-page: 1324 year: 2004 ident: 2023072512363768700_BIB41 publication-title: J. Virol. doi: 10.1128/JVI.78.3.1324-1332.2004 – volume: 76 start-page: 12423 year: 2002 ident: 2023072512363768700_BIB17 publication-title: J. Virol. doi: 10.1128/JVI.76.24.12423-12434.2002 – volume: 71 start-page: 1089 year: 1997 ident: 2023072512363768700_BIB48 publication-title: J. Virol. doi: 10.1128/jvi.71.2.1089-1096.1997 – volume: 407 start-page: 386 year: 2000 ident: 2023072512363768700_BIB23 publication-title: Nature. doi: 10.1038/35030124 – volume: 346 start-page: 1006 year: 1995 ident: 2023072512363768700_BIB2 publication-title: Lancet. doi: 10.1016/S0140-6736(95)91691-1 – volume: 88 start-page: 11047 year: 1991 ident: 2023072512363768700_BIB24 publication-title: Proc. Natl. Acad. Sci. USA. doi: 10.1073/pnas.88.24.11047 – volume: 10 start-page: 282 year: 2004 ident: 2023072512363768700_BIB45 publication-title: Nat. Med. doi: 10.1038/nm992 – volume: 169 start-page: 3447 year: 2002 ident: 2023072512363768700_BIB18 publication-title: J. Immunol. doi: 10.4049/jimmunol.169.6.3447 – volume: 191 start-page: 1499 year: 2000 ident: 2023072512363768700_BIB4 publication-title: J. Exp. Med. doi: 10.1084/jem.191.9.1499 – volume: 354 start-page: 453 year: 1991 ident: 2023072512363768700_BIB22 publication-title: Nature. doi: 10.1038/354453a0 – volume: 78 start-page: 3447 year: 2004 ident: 2023072512363768700_BIB29 publication-title: J. Virol. doi: 10.1128/JVI.78.7.3447-3454.2004 – volume: 128 start-page: 195 year: 2002 ident: 2023072512363768700_BIB32 publication-title: Clin. Exp. Immunol. doi: 10.1046/j.1365-2249.2002.01840.x – volume: 114 start-page: 250 year: 2004 ident: 2023072512363768700_BIB42 publication-title: J. Clin. Invest. doi: 10.1172/JCI200420985 – volume: 120 start-page: 512 year: 2001 ident: 2023072512363768700_BIB19 publication-title: Gastroenterology. doi: 10.1053/gast.2001.21212 – volume: 197 start-page: 1645 year: 2003 ident: 2023072512363768700_BIB7 publication-title: J. Exp. Med. doi: 10.1084/jem.20030239 – volume: 16 start-page: 364 year: 1998 ident: 2023072512363768700_BIB43 publication-title: Nat. Biotechnol. doi: 10.1038/nbt0498-364 – volume: 15 start-page: 883 year: 2001 ident: 2023072512363768700_BIB27 publication-title: Immunity. doi: 10.1016/S1074-7613(01)00245-X – volume: 75 start-page: 5550 year: 2001 ident: 2023072512363768700_BIB52 publication-title: J. Virol. doi: 10.1128/JVI.75.12.5550-5558.2001 – volume: 19 start-page: 69 year: 1997 ident: 2023072512363768700_BIB15 publication-title: Springer Semin. Immunopathol. doi: 10.1007/BF00945026 – volume: 191 start-page: 1853 year: 2000 ident: 2023072512363768700_BIB25 publication-title: J. Exp. Med. doi: 10.1084/jem.191.11.1853 – volume: 38 start-page: 433 year: 2004 ident: 2023072512363768700_BIB49 publication-title: Clin. Infect. Dis. doi: 10.1086/381097 – volume: 10 start-page: 275 year: 2004 ident: 2023072512363768700_BIB44 publication-title: Nat. Med. doi: 10.1038/nm998 – volume: 67 start-page: 4365 year: 1993 ident: 2023072512363768700_BIB50 publication-title: J. Virol. doi: 10.1128/jvi.67.7.4365-4368.1993 – volume: 62 start-page: 1009 year: 2001 ident: 2023072512363768700_BIB47 publication-title: Hum. Immunol. doi: 10.1016/S0198-8859(01)00298-1 – volume: 31 start-page: 2388 year: 2001 ident: 2023072512363768700_BIB14 publication-title: Eur. J. Immunol. doi: 10.1002/1521-4141(200108)31:8<2388::AID-IMMU2388>3.0.CO;2-L – volume: 96 start-page: 5692 year: 1999 ident: 2023072512363768700_BIB13 publication-title: Proc. Natl. Acad. Sci. USA. doi: 10.1073/pnas.96.10.5692 – volume: 30 start-page: 1037 year: 1999 ident: 2023072512363768700_BIB31 publication-title: Hepatology. doi: 10.1002/hep.510300403 – volume: 155 start-page: 431 year: 2000 ident: 2023072512363768700_BIB37 publication-title: Genetics. doi: 10.1093/genetics/155.1.431 – reference: 14576438 - Science. 2003 Oct 24;302(5645):659-62 – reference: 11356962 - J Virol. 2001 Jun;75(12):5550-8 – reference: 7593618 - J Clin Invest. 1995 Nov;96(5):2311-21 – reference: 14722287 - J Virol. 2004 Feb;78(3):1324-32 – reference: 11014195 - Nature. 2000 Sep 21;407(6802):386-90 – reference: 8838344 - Tissue Antigens. 1995 Nov;46(5):355-67 – reference: 9555728 - Nat Biotechnol. 1998 Apr;16(4):364-9 – reference: 8810254 - Science. 1996 Oct 4;274(5284):94-6 – reference: 8995629 - J Virol. 1997 Feb;71(2):1089-96 – reference: 12218168 - J Immunol. 2002 Sep 15;169(6):3447-58 – reference: 15067030 - J Exp Med. 2004 Apr 5;199(7):905-15 – reference: 10318946 - Proc Natl Acad Sci U S A. 1999 May 11;96(10):5692-7 – reference: 11543903 - Hum Immunol. 2001 Sep;62(9):1009-30 – reference: 12198669 - Hepatology. 2002 Sep;36(3):743-54 – reference: 15016867 - J Virol. 2004 Apr;78(7):3447-54 – reference: 11439948 - N Engl J Med. 2001 Jul 5;345(1):41-52 – reference: 14727218 - Clin Infect Dis. 2004 Feb 1;38(3):433-7 – reference: 8389933 - J Virol. 1993 Jul;67(7):4365-8 – reference: 11754811 - Immunity. 2001 Dec;15(6):883-95 – reference: 11861849 - J Virol. 2002 Mar;76(6):2817-26 – reference: 10790415 - Genetics. 2000 May;155(1):431-49 – reference: 10790425 - J Exp Med. 2000 May 1;191(9):1499-512 – reference: 12975468 - J Clin Invest. 2003 Sep;112(6):831-42 – reference: 15362033 - Gastroenterology. 2004 Sep;127(3):764-76 – reference: 10229187 - Immunity. 1999 Apr;10(4):439-49 – reference: 10839802 - J Exp Med. 2000 Jun 5;191(11):1853-67 – reference: 11714747 - J Exp Med. 2001 Nov 19;194(10):1395-406 – reference: 15254592 - J Clin Invest. 2004 Jul;114(2):250-9 – reference: 11985510 - Clin Exp Immunol. 2002 May;128(2):195-203 – reference: 14966520 - Nat Med. 2004 Mar;10(3):275-81 – reference: 11500822 - Eur J Immunol. 2001 Aug;31(8):2388-94 – reference: 10498657 - Hepatology. 1999 Oct;30(4):1037-44 – reference: 9018240 - Nat Med. 1997 Feb;3(2):205-11 – reference: 9410918 - J Clin Invest. 1997 Nov 1;100(9):2376-85 – reference: 11159892 - Gastroenterology. 2001 Feb;120(2):512-24 – reference: 15194783 - J Virol. 2004 Jul;78(13):7069-78 – reference: 14770175 - Nat Med. 2004 Mar;10(3):282-9 – reference: 12021343 - J Virol. 2002 Jun;76(12):6104-13 – reference: 7475549 - Lancet. 1995 Oct 14;346(8981):1006-7 – reference: 10764648 - Science. 2000 Apr 14;288(5464):339-44 – reference: 1721107 - Nature. 1991 Dec 12;354(6353):453-9 – reference: 12438568 - J Virol. 2002 Dec;76(24):12423-34 – reference: 8823309 - J Clin Invest. 1996 Sep 15;98(6):1432-40 – reference: 10500077 - Gastroenterology. 1999 Oct;117(4):933-41 – reference: 12527224 - Immunol Lett. 2003 Jan 22;85(2):165-71 – reference: 14694094 - J Virol. 2004 Jan;78(2):630-41 – reference: 1722316 - Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11047-51 – reference: 9266632 - Springer Semin Immunopathol. 1997;19(1):69-83 – reference: 11100119 - Nat Med. 2000 Dec;6(12):1348-54 – reference: 12909460 - Trends Immunol. 2003 Aug;24(8):456-64 – reference: 12810686 - J Exp Med. 2003 Jun 16;197(12):1645-55 |
| SSID | ssj0014456 |
| Score | 2.3137667 |
| Snippet | In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control... In the setting of acute hepatitis C virus (HCV) infection, robust HCV- specific CD8 super(+) cytotoxic T lymphocyte (CTL) responses are associated with initial... In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8 + cytotoxic T lymphocyte (CTL) responses are associated with initial control... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1593 |
| SubjectTerms | Acute Disease Amino Acid Sequence - genetics Amino Acid Substitution - genetics Amino Acid Substitution - immunology Animals CD8-Positive T-Lymphocytes - immunology Chronic Disease Epitopes, T-Lymphocyte - immunology Evolution, Molecular Female Genetic Variation - genetics Genetic Variation - immunology Hepacivirus - genetics Hepacivirus - immunology Hepatitis C - genetics Hepatitis C - immunology Hepatitis C - pathology Hepatitis C virus HLA-B8 Antigen - immunology Humans Lymphocyte Activation - immunology Male Molecular Sequence Data Mutation - genetics Mutation - immunology Viral Nonstructural Proteins - genetics Viral Nonstructural Proteins - immunology Viremia - immunology Viremia - pathology |
| Title | CD8 Epitope Escape and Reversion in Acute HCV Infection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/15611288 https://www.proquest.com/docview/17743061 https://www.proquest.com/docview/67186021 https://pubmed.ncbi.nlm.nih.gov/PMC2212005 |
| Volume | 200 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLdgSIgLGt_dBvgApyrgJHbsHKduU8c-uLSot8h2HK0SSiva7sBfz7OdOsnoxMclqlLLbv17cX5-fu_3EPqglQacdRxVlckiykweiczoSObwOmAp0UrZ3OGr62w8pV9mbNYW_nPZJWv1Sf_cmVfyP6jCPcDVZsn-A7KhU7gBnwFfuALCcP0rjEcnYmiW8EwuzdCsbCiTDxc3t94LZp0ZUttIgPHoW4i7qruEtE0Nc6S0J_h_99wdcPU51YutLJZTbNx41J13vXWuXkhbrtmf4Pg89raMl9WDnJfe9Xq-kvbsw_TcD07kMCHdJRV2szbUorukevXRYDtJZ4UE-pTuXLqJoHbpNk4egEKPOxSyr78WZ9PLy2JyOps8RI8S2BrYqhUn5xfh5IhSV7E3_Kwm2QF6_9ztu09Dfttb3A2R7XCOyT562uCCjz3yz9ADUz9Hj68aWF4gDgaAGwPA3gAwGAAOBoDnNXYGgMEAcDCAl2h6djoZjaOmEkakKc_XkZaxAqZBJOFVXhpmJGfw6GVJKRLJTAX_VpeCMCYp7OjTXEnGZZxXijNDSGnSV2ivXtTmDcKykllmu4uZopQTRQBlEXOeMlFpyQZouJ2YQjcy8bZayffChSsIWsA0FttpHKCPofXSy6Pc0-79do4LWL_soZSszWKzKmBkCtvW-P4WGdCnDKjoAL32mLQjAfkHfiUGiPfQCg2sdnr_m3p-4zTUE6Bs8AI6-OOoh-hJa_ZHaG_9Y2PeAg9dq3fO8H4BkiSKGw |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CD8+epitope+escape+and+reversion+in+acute+HCV+infection&rft.jtitle=The+Journal+of+experimental+medicine&rft.au=Timm%2C+Joerg&rft.au=Lauer%2C+Georg+M&rft.au=Kavanagh%2C+Daniel+G&rft.au=Sheridan%2C+Isabelle&rft.date=2004-12-20&rft.issn=0022-1007&rft.volume=200&rft.issue=12&rft.spage=1593&rft_id=info:doi/10.1084%2Fjem.20041006&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1007&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1007&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1007&client=summon |